

Message

From: Nalubola, Ritu [Ritu.Nalubola@fda.hhs.gov]
Sent: 4/21/2017 5:58:59 PM
To: McNally, Robert [McNally.Robert@epa.gov]
CC: Flamm, Eric [Eric.Flamm@fda.hhs.gov]; Epstein, Laura [Laura.Epstein@fda.hhs.gov]; Leahy, John [Leahy.John@epa.gov]
Subject: Follow-up items from Tuesday EPA-FDA mtg

Hi Bob – Circling back on the two items from Tuesday's mtg that were flagged for FDA follow-up:

Travel to FL – Thanks again for sharing this info and for the opportunity to accompany EPA colleagues. Considering resources, etc., we've decided not to have any FDA reps on this trip. I recall you said you'd be Ex. 6 - Personal Privacy so copying John, too.

Oxitec revised EA – The revised EA Oxitec submitted had several deficiencies and so CVM is sending it back to Oxitec. We will keep you posted of progress and will share the next iteration with you. I've copied Laura in case you have any specific questions about the EA content.

Thanks!

Ritu

Ritu Nalubola, Ph.D.
Senior Policy Advisor
Office of Policy, Office of the Commissioner
U.S. Food and Drug Administration
WO32, Room 4236
Phone: 301-796-3252
Fax: 301-847-3541
Email: Ritu.Nalubola@fda.hhs.gov